同仁堂科技(01666.HK)出資1,250萬人幣成立醫藥電商合資公司
同仁堂科技(01666.HK)公布,5月25日公司與同仁堂股份、同仁堂商業及白兔信息訂立合資合同,訂約方同意成立合資公司,從事醫藥電商業務。合資公司的註冊資本為5,000萬元人民幣(下同),公司、同仁堂股份、同仁堂商業及白兔信息同意分別出資1,250萬元、1,250萬元、1,300萬元及1,200萬元,分別佔合資公司註冊資本的25%、25%、26%及24%。
由於同仁堂股份直接持有公司46.85%股權,其為公司的直接控股股東,並因此為上市規則項下公司的關連人士。(el/w) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.